Ebonyi Augustine O, Oguche Stephen, Ejeliogu Emeka U, Agbaji Oche O, Shehu Nathan Y, Abah Isaac O, Sagay Atiene S, Ugoagwu Placid O, Okonkwo Prosper I, Idoko John A, Kanki Phyllis J
MBBS, MSc, Department of Pediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
BM. Bch, Department of Pediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Germs. 2016 Mar 1;6(1):21-8. doi: 10.11599/germs.2016.1085. eCollection 2016 Mar.
Studies on the prevalence of and risk factors for tuberculosis (TB) among newly diagnosed human immunodeficiency virus (HIV)-infected children in sub-Saharan Africa are scarce and in Nigeria there is paucity of reported data. We determined the prevalence of and risk factors for pulmonary TB (PTB) in newly diagnosed (treatment-naïve) HIV-1 infected children at the pediatric HIV clinic of the Jos University Teaching Hospital (JUTH) in Nigeria.
We performed a retrospective analysis of 876 children, aged 2 months - 13 years, diagnosed with HIV-1 infection between July 2005 and December 2012, of which 286 were diagnosed with PTB at presentation after TB screening. The study site was the AIDS Prevention Initiative in Nigeria (APIN)-supported Pediatric HIV clinic at JUTH, Jos. A multivariate forward logistic regression modelling was used to identify risk factors for PTB-HIV co-infection.
The prevalence of PTB-HIV co-infection was 32% (286/876). Severe immunosuppression (SI) and World Health Organization (WHO) HIV clinical stage 3/4 were identified as independent risk factors for PTB-HIV co-infection in HIV infected children. The odds of PTB-HIV co-infection was increased two-fold in HIV-infected children with WHO clinical stage 3/4 compared to those with stage 1/2 (adjusted odds ratio (AOR) 1.76 [1.31-2.37], p<0.001) and 1.5-fold in children with SI compared to those without SI (AOR 1.52 [1.12-2.06], p=0.007).
In our setting, the burden of PTB was high among newly diagnosed HIV-infected children, and late WHO HIV clinical stage and severe immunosuppression were associated with PTB-HIV co-infection. Therefore there is a clear need to improve strategies for early diagnosis of both HIV and PTB to optimize clinical outcomes.
关于撒哈拉以南非洲新诊断的感染人类免疫缺陷病毒(HIV)儿童中结核病(TB)的患病率及危险因素的研究较少,而在尼日利亚,报告的数据也很匮乏。我们在尼日利亚乔斯大学教学医院(JUTH)的儿科HIV诊所确定了新诊断(未接受过治疗)的HIV-1感染儿童中肺结核(PTB)的患病率及危险因素。
我们对2005年7月至2012年12月期间诊断为HIV-1感染的876名年龄在2个月至13岁的儿童进行了回顾性分析,其中286名在结核病筛查后初诊时被诊断为PTB。研究地点是乔斯JUTH的由尼日利亚艾滋病预防倡议(APIN)支持的儿科HIV诊所。采用多变量向前逻辑回归模型来确定PTB-HIV合并感染的危险因素。
PTB-HIV合并感染的患病率为32%(286/876)。严重免疫抑制(SI)和世界卫生组织(WHO)HIV临床分期3/4被确定为HIV感染儿童中PTB-HIV合并感染的独立危险因素。与临床分期1/2的HIV感染儿童相比,临床分期3/4的HIV感染儿童发生PTB-HIV合并感染的几率增加了两倍(调整后的优势比[AOR]为1.76[1.31-2.37],p<0.001);与无SI的儿童相比,有SI的儿童发生PTB-HIV合并感染的几率增加了1.5倍(AOR为1.52[1.12-2.06],p=0.007)。
在我们的研究环境中,新诊断的HIV感染儿童中PTB负担较高,WHO HIV临床分期较晚和严重免疫抑制与PTB-HIV合并感染有关。因此,显然需要改进HIV和PTB的早期诊断策略,以优化临床结果。